# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Laura Chico downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Neutral and announces $42 price...
Wells Fargo analyst Mohit Bansal downgrades Chinook Therapeutics (NASDAQ:KDNY) from Overweight to Equal-Weight and raises th...
HC Wainwright & Co. analyst Ed Arce reiterates Chinook Therapeutics (NASDAQ:KDNY) with a Neutral and maintains $40 price...
Evercore ISI Group analyst Josh Schimmer downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to In-Line and announ...